
Pancreatic Cancer
Latest News

Video Series
Latest Videos
Shorts




Podcasts
More News

After nearly a year of chemotherapy, a patient with stage 4 pancreatic cancer describes daily life and side effects on Rasonque (daraxonrasib).

From a new chemotherapy combination to the first RAS-targeted pill, here's what five years of pancreatic cancer approvals mean for patients.

In the phase 2 MASTERPLAN trial, adding SBRT to chemotherapy lowered the rate of cancer returning near the pancreas from 52.0% to 20.2% at one year.

New results for lung and pancreatic cancer show newer targeted drugs may help some patients live longer. Here is what patients and caregivers should know.

The FDA approved six cancer drugs in August 2026, including a landmark pancreatic cancer pill. Here's what each approval means for patients and side effects.

ASCO 2026 highlighted advances in pancreatic, breast, sarcoma, lung and prostate cancers that may reshape treatment.

ASCO 2026 will highlight biomarker-driven lung cancer care, targeted therapies, ADCs and phase 3 trials shaping precision oncology advances.

Dr. Paul Oberstein discusses how personalized mRNA vaccines may improve long-term survival for patients with pancreatic cancer.

Elraglusib plus chemotherapy doubled one-year survival in metastatic pancreatic cancer, showing improved outcomes in a phase 2 trial.

Daraxonrasib improved overall survival versus chemotherapy in metastatic pancreatic cancer.

Namodenoson was well tolerated in a phase 2a study of advanced pancreatic cancer, with one-third of patients alive at data cutoff.

The U.S. Food and Drug Administration has approved a new treatment for adults with locally advanced pancreatic cancer.

Dr. Meredith Pelster sat down for an interview with CURE to discuss new data surrounding new treatment outcomes for metastatic pancreatic cancer.

Ampligen and Imfinzi combination therapy demonstrated clinical activity for patients with metastatic pancreatic cancer.

Dr. Benjamin Jon Golas outlines pancreatic cancer care, including surgery, chemotherapy, radiation and emerging targeted therapies at specialized centers.

A potential new approach to treating advanced pancreatic cancer has shown benefit for patients, according to Dr. Eileen M. O'Reilly.




















